Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Dolutegravir und Rilpivirin, ATC J05AR21

Conclusion of non-exclusive rebate contracts pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the aforementioned active substance within the period from 01.08.2026 to 31.07.2028 with the possibility of concluding the contract at any time (open-house model). In the open house procedure, medicinal products according to the BfArM list pursuant to § 35 para. 5a SGB V (paediatric medicinal products) are excluded.